and negatively impacts quality of life (QOL) 1 .
• Further evidence is required to determine how treatments for OIC impact QOL in this group of patients. scores were collected at baseline, week 4, and week 12 and converted into estimates of utility using the Dolan algorithm, a tariff generated based on UK general population preferences 5 and according to published guidance. 6 -The health utility score was set to missing if 1 or more questions were not answered on the 5 dimensions of the EQ-5D.
-Based on the patient's response for each dimension, the health utility score was calculated by subtracting the time trade-off UK weights from 1 ( Table 1) . • An analytical dataset was created that included 1 record per patient per visit with nonmissing change from baseline in utility score.
• A time-dependent indicator of OIC state was derived (non-OIC=1, OIC=0, based on patient self-reports of ≥3 spontaneous bowel movements (SBMs) for ≥3 out of the previous 4 weeks or <3 SBMs for ≥2 out of the previous 4 weeks, respectively).
• Data were prospectively analyzed using a repeated measure mixedeffects model regression analysis to identify the effect of age, sex, race, body mass index, duration of opioid use, treatment (naloxegol 12.5 mg, naloxegol 25 mg, or placebo), baseline utility, and OIC status on the change from baseline in utility score using pooled data from weeks 4 and 12.
-Initially, each variable was examined in univariate regression models to assess the statistical significance of their association with outcome, defined as P≤0.1.
-A first multivariate model was then fitted by including the predictors identified in the previous step and subsequently trimmed down to retain only the significant or important variables.
-Key variables (eg, study week and treatment) were reincorporated into the trimmed multivariate model and reassessed for significance to ensure that no clinically significant variables were missed.
-The multivariate models were fitted in the ITT and laxativeinadequate response (LIR) populations where LIR was defined as taking laxatives for ≥4 days within 2 weeks before screening plus self-rated moderate, severe or very severe stool symptoms.
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RESULTS
• Baseline utility across all patients was 0.559 (SE 0.297) and was similar across treatment arms (placebo, 0.557; naloxegol 12.5 mg, 0.548; naloxegol 25 mg, 0.573).
• In the total pooled phase 3 population, the only significant predictors of change in utility score were the baseline utility score (P<0.001) and OIC status (P=0.01; Table 2 ).
-Inclusion of treatment, OIC status, and baseline utility in the model showed that treatment was not a significant predictor after controlling for its impact on OIC status (P=0.41).
-Additional inclusion of the interaction of OIC status and treatment in the model revealed that although this interaction was not significant after controlling for its impact on OIC status (P=0.33), OIC status continued to have a large impact on utility (P=0.01). • Similar results were observed for the pooled phase 3 population subgroup of patients with LIR (Table 3 ).
• Significant predictors of change in utility score for the pooled phase 3 LIR population were the baseline utility score (P<0.001) and OIC status (P<0.01; Table 3 ).
-Treatment was not a significant predictor after controlling for its impact on OIC status (P=0.41) when treatment, OIC status, and baseline utility were included in the model.
-The model incorporating treatment, OIC status, baseline utility, and the interaction of OIC status and treatment demonstrated a lack of interaction between OIC status and treatment (P=0.70) and a large effect of OIC status on utility (P=0.01).
-The model incorporating OIC status, baseline utility, and the interaction of OIC status and treatment also demonstrated a lack of interaction between OIC status and treatment (P=0.81) and a large effect of OIC status on utility (P=0.01). • Univariate analysis of OIC status in patient subgroups with different experiences of laxative treatment revealed that OIC status had an increased and meaningful impact on patients who had previously responded inadequately to laxatives (P=0.02).
CONCLUSIONS
• OIC status is a significant factor in the impact of treatment on patient's health state utility.
• Greater impact was observed in the subgroup of patients who had previously responded inadequately to laxatives.
• At baseline, patients with OIC have low EQ-5D scores, so a better understanding of the relationship between OIC status and patient utility would assist efforts to understand and improve quality of life in patients with OIC.
